ArticlePloS one2015
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Systematic online living evidence summaries: emerging tools to accelerate evidence synthesis.Clinical science (London, England : 1979) · 2023Pooled it
- Pooled it
- Role of lipoic acid in multiple sclerosis.CNS neuroscience & therapeutics · 2022Pooled it
- D-galactose-induced brain ageing model: A systematic review and meta-analysis on cognitive outcomes and oxidative stress indices.PloS one · 2017Pooled it
- Trial
- Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.The Lancet. Neurology · 2020Trial
- Trial
- Repurposed drug prioritization pipeline for a multi-arm platform trial in clinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Kynurenines and Inflammation: A Remarkable Axis for Multiple Sclerosis Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Drug Repurposing for Identification of S1P1 Agonists with Potential Application in Multiple Sclerosis Using In Silico Drug Design Approaches.Advanced pharmaceutical bulletin · 2023Article
- What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.Journal of molecular cell biology · 2021Review
- Riboflavin in Neurological Diseases: A Narrative Review.Clinical drug investigation · 2021Review
- Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective.Brain communications · 2021Review
- Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020Review
- Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?Molecules (Basel, Switzerland) · 2020Review
- Are large simple trials for dementia prevention possible?Age and ageing · 2020Article
- Dietary Inflammatory Index and clinical course of multiple sclerosis.European journal of clinical nutrition · 2019Article
- Article
- Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1α Stabilization.Molecular neurobiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo develop and implement an evidence based framework to select, from drugs already licenced, candidate oral neuroprotective drugs to be tested in secondary progressive multiple sclerosis.
designSystematic review of clinical studies of oral putative neuroprotective therapies in MS and four other neurodegenerative diseases with shared pathological features, followed by systematic review and meta-analyses of the in vivo experimental data for those interventions. We presented summary data to an international multi-disciplinary committee, which assessed each drug in turn using pre-specified criteria including consideration of mechanism of action.
resultsWe identified a short list of fifty-two candidate interventions. After review of all clinical and pre-clinical evidence we identified ibudilast, riluzole, amiloride, pirfenidone, fluoxetine, oxcarbazepine, and the polyunsaturated fatty-acid class (Linoleic Acid, Lipoic acid; Omega-3 fatty acid, Max EPA oil) as lead candidates for clinical evaluation.
conclusionsWe demonstrate a standardised and systematic approach to candidate identification for drug rescue and repurposing trials that can be applied widely to neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.